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Conservative as well as surgical management through liver trans-
plantation (LT) for patients with acute liver failure (ALF) has been
constantly improving for the past three decades. Data on the
long-term prognosis of patients with ALF who underwent LT
are scarce. Consequently, the two large data bases, namely the
US UNOS [1] and the European Liver Transplant Registry (ELTR)
[2], have been invaluable resources which had a major impact
on a remarkable progress in the management of such patients.
The ELTR data base contains selective information collected since
1968 and from 1985 prospectively, on LT performed in over
87,000 patients in 143 centers and 25 European countries [2,3].
The registry contains a wealth of information on a wide range
of parameters including epidemiological and demographic char-
acteristics of liver donors and recipients, quality and size of the
grafts, complications of surgery, survival and more.
In the present issue of the Journal, Germani and co-workers
have used the ELTR data base to analyze the risk factors which
govern the up to 10 year survival rates of patients and grafts in
ALF patients who underwent LT [4]. The studied associated risk
factors include among others, the etiology of ALF, donor and reci-
pient age, gender, blood group matching, total ischemic time of
the graft, graft type, surgical technique, and causes of graft failure
or death. These were evaluated in a cohort of 4903 adults who
underwent LT between 1988 and 2009 [4]. Space limitations for
comments do not enable a detailed discussion of data. However,
several conclusions can be drawn from the major ﬁndings of this
important study: Survival of grafts and patients in Europe has
improved signiﬁcantly for the years 2004–2009 as compared to
three previous 4–5 year periods between 1988 and 2003.
Although mortality during the ﬁrst year after LT for ALF still
remains relatively high, the recent 1, 5, and 10 years patients/
graft survival rates were 74/63%, 68/57%, and 63/50%, respec-
tively. The increased survival rates of European ALF patients are
especially evident in the cohort of 2004–2009 LT patients. Data
presented in Figs. 2A and B, suggest indeed a progressive
improvement in survival, especially in the ﬁrst year post LT. ThisJournal of Hepatology 20
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factors including intensive and medical care, in surgical tech-
niques and experience as well as in efﬁcacy of anti-rejection
agents. As also shown in the US, long-term survival of ALF
patients after LT is lower as compared to results in patients with
chronic liver disease (CLD). There are some minor differences in
reports on survival rates of ALF patients one year after LT
between patients in the US and Europe at 82% and 74%, respec-
tively. However, such a comparison is inaccurate and does not
diminish the importance of the continuous advance in the man-
agement of patients which has occurred despite a 10-fold rise
in the rates of organ donors above the age of 60 years. In this
study, the investigators employed 3- and 12-month prognostic
models to identify potential risk factors associated with the
relatively high mortality of ALF patients in the ﬁrst year post
ALT. Despite some limitations, mainly regarding the 12-month
model, the results obtained through these tools suggest that the
major risk factors with a detrimental impact on mortality post
LT include, donor age >60 years, recipient age >50 years, the use
of reduced size grafts and incompatible ABO blood group
matching.
Although known for several years, one ﬁnding of the present
analysis is of particular concern, namely the 7-fold rise from
2.0% to 14.1% in the number of patients undergoing LT for para-
cetamol-induced ALF. Not less disturbing is the 8% loss of graft
or life due to repeated suicide or lack of compliance. These data
suggest that such patients need a very close post transplant sup-
port including better social and psychologic care. Ideally, such
high risk patients should be identiﬁed prior to referral for LT.
However, the urgency in performing LT usually prevents an in
depth psychiatric analysis pre-transplant.
As also acknowledged by the investigators, there are some
limitations in the use of the ELTR data base in the models for
the assessment of prognosis of LT patients in this study. These
include the lack of information regarding pre-transplant renal
function, ventilation status, as well as degree of hepatic enceph-
alopathy and brain edema. Furthermore, the etiology of fulmin-
ant hepatitis is highly variable in different geographic regions
within Europe which has an impact on pre and post transplant
prognosis. For example, paracetamol intoxication is more preva-
lent in the UK and Northern Europe. In contrast, viral hepatitis B
and A, although in decline following introduction of vaccination
and anti-viral therapy, are more prevalent in Southern European
countries.12 vol. 57 j 233–234
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In summary, taking into account some limitations of the
structure of ELTR data base and analysis of the large set of data,
this extensive report provides a wealth of information which is
of great value to hepatologist, intensive care experts, and
surgeons taking care of these sick ALF patients. Despite the major
progress made in our ability to predict the probability of sponta-
neous recovery of patients with ALF, this remains an ongoing and
difﬁcult challenge. Following the analysis in the discussed report,
the task becomes even more difﬁcult. When bad prognostic fac-
tors such as older age of donor and recipient as well as ABO mis-
match and/or use of reduced graft size cluster together, such
circumstances suggest that survival after LT will be signiﬁcantly
impaired and mortality may reach >50%, a ﬁgure which appears
unacceptable.Conﬂict of interest
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